News

Teladoc (TDOC) concluded the recent trading session at $7.81, signifying a +1.56% move from its prior day's close.

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Teladoc (TDOC) reached $7.57 at the closing of the latest trading day, reflecting a +1.47% change compared to its last close.

Analyst sentiment shift and near term expectations Teladoc Health (TDOC) is back on investors’ radar after analysts turned more positive in their earnings estimates, even as they still expect a 26.32% year over year decline in the upcoming report. This change in sentiment, paired with a recent 1.44% gain that outperformed key indices, has focused attention on how the company’s virtual care and mental health businesses might shape near term performance. See our latest analysis for Teladoc...

Teladoc (TDOC) reached $7.03 at the closing of the latest trading day, reflecting a +1.44% change compared to its last close.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Teladoc Health delivers virtual care worldwide; a key insider recently exited their stake, according to the latest SEC filing.

TDOC gains on Integrated Care growth, international expansion and cost cuts, but BetterHelp weakness and ongoing losses remain key challenges.

A number of stocks fell in the afternoon session after rising Treasury yields compressed valuations for growth-oriented names as geopolitical uncertainty dulled the advertising outlook.

In late May 2026, Walmart announced that Teladoc Health’s virtual urgent care, dermatology, and nutrition services are now available on its Better Care Services platform, offering both insured and US$89 cash‑pay visits with integrated pharmacy fulfillment across nearly 5,000 locations. This partnership broadens Teladoc’s retail footprint and reinforces its push to meet patients on large consumer platforms, complementing January’s launch of BetterHelp mental health services on Walmart’s care...

Teladoc stock rallies on an extended partnership with Walmart. But TDOC shares remain unattractive to own at current levels.

Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

TDOC teams with Walmart to offer virtual urgent care, dermatology and nutrition services, expanding affordable telehealth access nationwide.

Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 11.3% in the afternoon session after it announced its virtual care services are now available through Walmart's Better Care Services platform.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Teladoc (NYSE:TDOC) and the rest of the online marketplace stocks fared in Q1.

Teladoc’s Walmart partnership is the latest step in its push to embed its services with retailers and platforms Americans already use.

Teladoc Health Inc (NYSE:TDOC) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. On May 1, Jefferies raised its price target Teladoc shares to $6 from $5.20 while keeping a Hold rating on the stock. Even so, the firm’s new price target remains below Teladoc’s current […]

It would be quite the feat for this struggling company.

Teladoc Health (NYSE:TDOC) is reporting flat sales over consecutive years, despite continued investment in its virtual care platform. Average revenue per user has been declining, pointing to weaker consumer monetization and softer engagement levels. Management has focused on broadening services, but this has not translated into stronger top line growth or higher earnings quality. The outlook for the next twelve months remains subdued, highlighting ongoing challenges for the...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Teladoc currently trades at $6.81 per share and has shown little upside over the past six months, posting a small loss of 1.6%. The stock also fell short of the S&P 500’s 9.9% gain during that period.

Cathie Wood‘s ARK Invest joined Kalshi’s $1 billion Series F last week at a $22 billion valuation, slotting the prediction market behind only SpaceX and OpenAI in the ARK Venture Fund. Wood called prediction markets “a powerful new layer of financial infrastructure.” Kalshi will be hoping this prediction is more accurate than many of her previous ones. A Decade Of Big Calls That Did Not Land Morningstar analyst Amy Arnott labeled the ARK fund family the worst wealth destroyer of any U.S. fund gr

If you are trying to figure out whether Teladoc Health is attractively priced or not, the recent share moves give you plenty to think about. The stock last closed at US$6.66, with returns of 11.0% over the past week and 26.4% over the past month, while the year-to-date return is a 5.5% decline and the 1-year return is a 1.8% decline, alongside a 73.4% decline over 3 years and a 95.4% decline over 5 years. Recent coverage has focused on Teladoc Health's position in telehealth and digital care...

Teladoc Health posts a y/y narrower Q1 loss and beats revenue estimates as international growth and cost cuts offset BetterHelp weakness and subscription declines.

Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 7.1% in the afternoon session after the stock's positive momentum continued as it raised its price target on the stock to $9.00 from $8.25 and maintained a Buy rating.

Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company’s guidance for both revenue and Adjusted EBITDA, driven by solid performance in Integrated Care and continued progress scaling BetterHelp’s insuranc